Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies (NYSE: A) has declared a quarterly dividend of 24.8 cents per share of common stock. The dividend will be paid on July 23, 2025, to shareholders of record as of July 1, 2025. The company notes that future dividend amounts and timing will be subject to board approval.
Agilent Technologies (NYSE: A) has announced two significant additions to its Board of Directors: Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, effective May 21, 2025. Soriot brings extensive pharmaceutical industry experience as AstraZeneca's CEO since 2012, while Gawlik Brown contributes substantial financial and strategic expertise from her roles at Perrigo Company and Amgen. The appointments coincide with Agilent's three-year Ignite Transformation initiative.
Simultaneously, Heidi Kunz is retiring from the Board after more than 20 years of service, having joined at the company's inception in 2000. Agilent, which generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide, continues its commitment to balanced Board refreshment.
TORM plc (NASDAQ: TRMD) has announced a capital increase through the issuance of 151,581 A-shares at a nominal value of USD 1,515.81. This increase results from the exercise of Restricted Share Units as part of the company's incentive program. The new shares were subscribed for in cash at DKK 0.08 per A-share.
Following the capital increase, TORM's total share capital now stands at USD 984,345.66, consisting of 98,434,564 A-shares, one B-share, and one C-share, each with a nominal value of USD 0.01. The A-shares carry a total of 98,434,564 votes, while the B and C shares have specific voting rights. The new shares are expected to be listed on Nasdaq Copenhagen soon.
TORM plc (NASDAQ: TRMD) has reported an insider transaction involving CEO and Executive Director Jacob Balslev Meldgaard. The executive exercised 33,559 restricted share units at a price of DKK 0.08 per share, totaling DKK 2,684.72. The transaction was executed on May 19, 2025, outside a trading venue.
TORM is a leading carrier of refined oil products, operating a fleet of product tanker vessels with a focus on safety and environmental responsibility. The company, founded in 1889, has its shares listed on both Nasdaq Copenhagen and Nasdaq New York.
Agilent Technologies (NYSE: A) announced that CEO Padraig McDonnell and CFO Bob McMahon will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 4, 2025, at 10:30 a.m. Eastern in New York City. Investors and interested parties can access a live audio webcast and replay of the presentation through the Agilent Investor Relations website.
Crawford & Company (NYSE: CRD-A and CRD-B) has announced its quarterly dividend declaration following its regular board meeting on May 7, 2025. The company will distribute a dividend of $0.07 per share for both Class A and Class B Common Stock. The dividend will be paid on June 6, 2025, to shareholders who are on record as of the market close on May 23, 2025.
Summary not available.
TORM plc (NASDAQ: TRMD) has announced a capital increase through the issuance of 18,769 A-shares, with a nominal value of USD 187.69, following the exercise of Restricted Share Units as part of its incentive program. The new shares were subscribed for in cash at DKK 0.08 per A-share.
The new ordinary shares will carry standard rights, including dividend eligibility from the issuance date, and are expected to be listed on Nasdaq Copenhagen. Following this capital increase, TORM's total share capital stands at USD 982,829.85, consisting of 98,282,983 A-shares, one B-share, and one C-share, each with a USD 0.01 par value. The A-shares carry 98,282,983 votes, while the B and C shares maintain specific voting rights.
Agilent Technologies (NYSE: A) has announced its participation at the AACR Annual Meeting 2025 in Chicago, showcasing innovative cancer research solutions. The company unveiled three new Avida DNA Cancer Panels for ultra-sensitive detection of cancer genomic alterations from liquid biopsies, featuring a streamlined 5-hour workflow.
Key highlights include partnerships with Tagomics for their Interlace Multiomics assay integration with Agilent's SureSelect Cancer CGP assay, and collaboration with Roswell Park Cancer Center for the SureSelect Cancer Pan Heme Assay. Additionally, Agilent announced a strategic partnership with Abcam for IHC Companion Diagnostics development using Abcam's portfolio of over 10,000 recombinant monoclonal antibodies.